Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

News Daily News

CV Death Rates in Autoimmune Disorders Waning, but Still Higher in Women

L.A. McKeown

May 14, 2025

News Daily News

Lingering Gaps in CVD Care for Women Spotlighted in British Consensus Statement

Todd Neale

September 26, 2024

News Daily News

Temperature Highs and Lows Leave Their Mark on CV Deaths

L.A. McKeown

June 03, 2024

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

L.A. McKeown

November 08, 2023

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

L.A. McKeown

May 12, 2023

News Daily News

SURMOUNT-1: Tirzepatide Drastically Reduces Weight in Obese Patients

L.A. McKeown

June 09, 2022

News Daily News

Infertility in Women Linked to Subsequent Risk of HFpEF

L.A. McKeown

April 19, 2022

News Daily News

Women Less Likely Than Men to Experience SCD During Sports

Michael O'Riordan

December 21, 2021

News Daily News

Hormone Cancer Therapies Increase CV Risk: AHA Scientific Statement

Yael L. Maxwell

April 26, 2021

News Daily News

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

Yael L. Maxwell

May 28, 2020

News Conference News HFSA 2019

Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention

L.A. McKeown

September 24, 2019

News Daily News

VTE Risk in Women May Be Higher With Oral vs Transdermal Hormone Replacement Therapies

L.A. McKeown

January 14, 2019

News Daily News

Healthcare Spending on the Rise for Working-Age Adults With Hypertension

Todd Neale

March 07, 2018

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

Advertisement

What’s Going to Be Hot at AHA 2025?

CV Death Rates in Autoimmune Disorders Waning, but Still Higher in Women

Lingering Gaps in CVD Care for Women Spotlighted in British Consensus Statement

Temperature Highs and Lows Leave Their Mark on CV Deaths

FDA Grants Tirzepatide a New Indication for Obesity Management

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

SURMOUNT-1: Tirzepatide Drastically Reduces Weight in Obese Patients

Infertility in Women Linked to Subsequent Risk of HFpEF

Women Less Likely Than Men to Experience SCD During Sports

Hormone Cancer Therapies Increase CV Risk: AHA Scientific Statement

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention

VTE Risk in Women May Be Higher With Oral vs Transdermal Hormone Replacement Therapies

Healthcare Spending on the Rise for Working-Age Adults With Hypertension

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content